Development of a High Performance Bioreactor

高性能生物反应器的开发

• 批准号: 6943873
• 负责人: TODD A MCADAMS
• 金额: $ 31.49万
• 依托单位: RESODYN CORPORATION
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-15 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6943873
• 关键词: Fungi; Mammalia; biomedical equipment development; bioreactors; cell proliferation; fermentation; fluidity; gene expression; microorganism culture; microorganism growth; monoclonal antibody; oxygen transport; tissue /cell culture

DESCRIPTION (provided by applicant): The Phase II project specific aim is to perform research to develop and demonstrate an advanced, High Performance Bioreactor (HPBR) fermentation technology that enhances growth characteristics and product expression for various cellular organisms, e.g., bacteria, fungi, yeast, plant, insect and mammalian cells. The HPBR is based upon a novel low-frequency resonant, low-shear mixing technology that has been demonstrated to provide greatly increased oxygen transfer rates and considerably improved mixing compared to conventional technology. The work conducted in Phase I provided compelling evidence that the HPBR is an improved method for the growth and volumetric productivity of a broad range of organisms and pharmaceutical products. The technology has application as both a discovery tool and as an efficient method for production of biopharmaceuticals. The major commercialization opportunity for the HPBR is the culture of hybridoma cells for the production of monoclonal antibodies (MAb). The market for MAb's is projected to grow at a compound rate of 20% over the next 10 years, to $6 billion and serious shortage of production capacity is foreseen. The HPBR technology offers an order of magnitude increase in process intensity compared to conventional stirred bioreactors.

描述（由申请人提供）：II期项目的特定目的是进行研究，以开发和展示高级生物反应器（HPBR）发酵技术，从而增强了各种细胞生物的生长特征和产物表达，例如细菌，真菌，酵母，酵母，植物，昆虫，昆虫和哺乳动物细胞。 HPBR基于一种新型的低频谐振剂，低剪切混合技术，与常规技术相比，已证明可以大大提高氧气转移速率并大大改善混合。在第一阶段进行的工作提供了令人信服的证据，表明HPBR是改进的多种生物和药品的生长和体积生产率的改进方法。该技术既应用于发现工具，也是生产生物药物的有效方法。 HPBR的主要商业化机会是产生单克隆抗体（MAB）的杂交瘤细胞培养。 MAB的市场预计将在未来10年内以20％的复合率增长，达到60亿美元，并且预计生产能力的严重短缺。与传统的搅拌生物反应器相比，HPBR技术的过程强度增加了数量级。